Last reviewed · How we verify
lumefantrine-artemether
Lumefantrine and artemether are antimalarial agents that work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and generating reactive oxygen species.
Lumefantrine and artemether are antimalarial agents that work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and generating reactive oxygen species. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.
At a glance
| Generic name | lumefantrine-artemether |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Antimalarial combination |
| Target | Malaria parasite (Plasmodium) hemoglobin metabolism and mitochondrial function |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Artemether, a artemisinin derivative, rapidly reduces parasite biomass by generating free radicals that damage parasite proteins and membranes. Lumefantrine, a biguanide-like compound, inhibits parasite heme polymerization and disrupts mitochondrial function. Together, they provide rapid parasite clearance and extended post-treatment suppression of parasitemia.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria caused by Plasmodium vivax, ovale, and malariae
Common side effects
- Headache
- Fever
- Nausea
- Abdominal pain
- Diarrhea
- Dizziness
Key clinical trials
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) (PHASE2)
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (PHASE4)
- CHILD (Child Health and Infection With Low Density) Malaria (NA)
- Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria (PHASE3)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lumefantrine-artemether CI brief — competitive landscape report
- lumefantrine-artemether updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI